Johnson & Johnson (NYSE:JNJ) Given New $255.00 Price Target at Royal Bank Of Canada

Johnson & Johnson (NYSE:JNJ) had its price target lifted by equities research analysts at Royal Bank Of Canada from $240.00 to $255.00 in a report released on Tuesday, MarketBeat Ratings reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price points to a potential upside of 8.91% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Wolfe Research raised their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Guggenheim upped their target price on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Morgan Stanley set a $262.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Wednesday, January 28th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $233.73.

Johnson & Johnson Stock Up 1.5%

Shares of NYSE JNJ traded up $3.40 during mid-day trading on Tuesday, reaching $234.15. The company had a trading volume of 1,138,793 shares, compared to its average volume of 9,076,730. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $235.20. The stock’s 50 day moving average is $211.21 and its 200-day moving average is $192.24. The stock has a market capitalization of $564.13 billion, a PE ratio of 21.23, a price-to-earnings-growth ratio of 2.21 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting the consensus estimate of $2.46. The company had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently bought and sold shares of the business. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $26,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson during the fourth quarter worth $26,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $28,000. Finally, DecisionPoint Financial LLC lifted its holdings in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.